Allen A. Mitchell

Allen A. Mitchell

Auto-generated profile, based on publicly available information

Allen A. Mitchell

Slone Epidemiology Center at Boston University, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2002 in JAMA
Verified
Journal Article
Open access
PDF file
DKDavid W. Kaufman
David W. Kaufman
JKJudith P. Kelly
Judith P. Kelly
LRLynn Rosenberg
Lynn Rosenberg
TATheresa E. Anderson
Theresa E. Anderson
AMAllen A. Mitchell
Allen A. Mitchell
A large number and wide variety of medications approved for use by the US Food and Drug Administration (FDA) are available to the US population, and expenditures on drugs have increased dramatically in recent years.1-3 New prescription drugs are continually introduced, and older drugs are increasingly available over the counter (OTC), making self-medication commonplace. Adverse reactions to drugs are among the leading causes of hospitalization and death in this country.4,5 At the same time, there has been a considerable increase in the use of herbal products and other natural supplements6,7 (henceforth referred to as "herbals/supplements"), which by law are not subject to FDA regulation. Although these products may be taken concurrently with regulated medications, health care professionals are often not informed of such use by their patients.7 Evidence is growing that many herbals/supplements have pharmacologic activity that can lead to clinically serious adverse interactions when they are taken together with regulated drugs,8 but there is little information available to estimate the potential magnitude of this problem.

15 January 2002 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MHMiguel A Hernán
Miguel A Hernán
SHSonia Hernández-Díaz
Sonia Hernández-Díaz
MWMartha M Werler
Martha M Werler
AMAllen A Mitchell
Allen A Mitchell
Common strategies to decide whether a variable is a confounder that should be adjusted for in the analysis rely mostly on statistical criteria. The authors present findings from the Slone Epidemiology Unit Birth Defects Study, 1992–1997, a case-control study on folic acid supplementation and risk of neural tube defects. When statistical strategies for confounding evaluation are used, the adjusted odds ratio is 0.80 (95% confidence interval: 0.62, 1.21). However, the consideration of a priori causal knowledge suggests that the crude odds ratio of 0.65 (95% confidence interval: 0.46, 0.94) should be used because the adjusted odds ratio is invalid. Causal diagrams are used to encode qualitative a priori subject matter knowledge.

1 July 2011 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
AMAllen A. Mitchell
Allen A. Mitchell
SGSuzanne M. Gilboa
Suzanne M. Gilboa
MWMartha M Werler
Martha M Werler
KKKatherine E. Kelley
Katherine E. Kelley
CLCarol Louik
Carol Louik
SHSonia Hernández-Díaz
Sonia Hernández-Díaz

9 February 2006 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
CCChristina D Chambers
Christina D Chambers
SHSonia Hernandez-Diaz
Sonia Hernandez-Diaz
LMLinda J. Van Marter
Linda J. Van Marter
MWMartha M Werler
Martha M Werler
CLCarol Louik
Carol Louik
AMAllen A. Mitchell
Allen A. Mitchell
Persistent pulmonary hypertension of the newborn (PPHN) is associated with substantial infant mortality and morbidity. A previous cohort study suggested a possible association between maternal use of the selective serotonin-reuptake inhibitor (SSRI) fluoxetine late in the third trimester of pregnancy and the risk of PPHN in the infant. We performed a case–control study to assess whether PPHN is associated with exposure to SSRIs during late pregnancy. Between 1998 and 2003, we enrolled 377 women whose infants had PPHN and 836 matched control women and their infants. Maternal interviews were conducted by nurses, who were blinded to the study hypothesis, regarding medication use in pregnancy and potential confounders, including demographic variables and health history. Fourteen infants with PPHN had been exposed to an SSRI after the completion of the 20th week of gestation, as compared with six control infants (adjusted odds ratio, 6.1; 95 percent confidence interval, 2.2 to 16.8). In contrast, neither the use of SSRIs before the 20th week of gestation nor the use of non-SSRI antidepressant drugs at any time during pregnancy was associated with an increased risk of PPHN. These data support an association between the maternal use of SSRIs in late pregnancy and PPHN in the offspring; further study of this association is warranted. These findings should be taken into account in decisions as to whether to continue the use of SSRIs during pregnancy.

30 November 2000 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SHSonia Hernández-Díaz
Sonia Hernández-Díaz
MWMartha M Werler
Martha M Werler
AWAlexander M. Walker
Alexander M. Walker
AMAllen A. Mitchell
Allen A. Mitchell
Multivitamin supplementation in pregnant women may reduce the risks of cardiovascular defects, oral clefts, and urinary tract defects in their infants. We evaluated whether the folic acid component of multivitamins is responsible for the reduction in risk by examining the associations between maternal use of folic acid antagonists and these congenital malformations.

28 June 2007 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
CLCarol Louik
Carol Louik
ALAngela E. Lin
Angela E. Lin
MWMartha M Werler
Martha M Werler
SHSonia Hernández-Díaz
Sonia Hernández-Díaz
AMAllen A. Mitchell
Allen A. Mitchell
The risk of birth defects after antenatal exposure to selective serotonin-reuptake inhibitors (SSRIs) remains controversial.